Type-Specific Epidemiology and Risk Factors for Human Papillomavirus Infection in Young Women.
Tasneem Shikary BA BS, David I. Bernstein MD MA, Yan Jin PhD, Gregory D. Zimet PhD, Susan L. Rosenthal PhD, Monica McNeal, Dick Ward PhD, Jessica A. Kahn, MD MPH
Division of Adolescent Medicine and Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center;University of Cincinnati College of Medicine; Indiana University, University of Texas, Medical Branch at Galveston

Objective: The objectives of this study were to: 1) determine the prevalence of any HPV, high-risk HPV, and vaccine-type HPV in sexually experienced 13-26 year-old young women within the first year post-licensing of the quadrivalent HPV-6, -11, -16, -18 vaccine, and 2) determine which demographic, gynecologic, cognitive, attitudinal, and behavioral factors as associated with high-risk and vaccine type HPV in this population.

Methods: Sexually experienced women aged 13-26 (N=409) were recruited from three clinics. All participants completed a survey instrument assessing demographic, gynecologic, cognitive, attitudinal, and behavioral characteristics and submitted cervicovaginal swabs for HPV DNA testing. Outcome measures were prevalence of high-risk type HPV and prevalence vaccine type HPV. Variables independently associated with high-risk and vaccine-type HPV were determined using unadjusted and adjusted logistic regression models.

Results: The overall prevalence of HPV was 68.4%; 59.5% were positive for ≥ 1 high-risk HPV type and were detected in 59.5%and 33.1% were positive for ≥ 1 vaccine-type HPV. The most common HPV types detected were HPV-52 (detected in 19.0%), HPV-16 (17.3%), HPV-18 (11.6%), HPV-59 (10.1%), HPV-CP610 (10.1%), HPV-6 (9.4%), HPV-66 (8.4%), HPV-51 (8.2%), and HPV-58 (8.2%). Variables independently associated with high-risk HPV infection were Black race (OR 2.03, 95% CI 1.21-.341) and lifetime number of male sexual partners > 2 (e.g. OR for 3 vs. ≤ 1 partner 3.58, 95% CI 1.61-7.96). No variables were consistently associated with vaccine-type HPV infection.

Conclusion: In this sample of low income adolescent women the overall prevalence of HPV was high, characteristic of urban populations; however, it was significantly higher than HPV prevalence in nationally representative samples. Vaccine-type HPVs were commonly detected in HPV positive women, though none of the women were infected with all four vaccine-type HPVs which supports recommendations to vaccinate 13-26 year-old women even if they are sexually active. None of the variables were associated with vaccine-type HPV infection, supporting national recommendations for universal HPV vaccination.